Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
- PMID: 19680292
- DOI: 10.1038/onc.2009.197
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
Abstract
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease. Current treatment paradigms are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. As patient responses to these therapies vary, predictive biomarkers will be an important facet of a patient's diagnostic workup in personalized medicine, as there is accumulating evidence that they may enable the prognostication and prediction of therapeutic response. Potential biomarkers for the selection of patients with NSCLC most likely to benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, include mutations, gene copy number increase and single-nucleotide polymorphisms of the EGFR gene, EGFR protein expression and oncogenic mutation on the KRAS gene. Many techniques are available to assay for these biomarkers. In this review, we present the current weight of evidence for using these methods as biomarkers for anti-EGFR therapy in patients with NSCLC.
Similar articles
-
The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.Oncogene. 2009 Aug;28 Suppl 1:S1-3. doi: 10.1038/onc.2009.195. Oncogene. 2009. PMID: 19680291
-
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29. J Clin Pathol. 2012. PMID: 22039281 Review.
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. doi: 10.1158/1078-0432.CCR-07-0332. Clin Cancer Res. 2007. PMID: 17671150 Review.
-
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555. Clin Cancer Res. 2006. PMID: 16857820 Review.
-
EGFR FISH versus mutation: different tests, different end-points.Lung Cancer. 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. Epub 2008 Mar 25. Lung Cancer. 2008. PMID: 18367287 Review.
Cited by
-
Effects of Resveratrol on Receptor Expression and Serum Levels of Estrogen and Progesterone in the Rat Endometritis Model.Reprod Sci. 2021 Sep;28(9):2610-2622. doi: 10.1007/s43032-021-00586-3. Epub 2021 May 8. Reprod Sci. 2021. PMID: 33966185
-
Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer.Cancers (Basel). 2022 Dec 15;14(24):6209. doi: 10.3390/cancers14246209. Cancers (Basel). 2022. PMID: 36551695 Free PMC article.
-
Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.Breast Cancer Res. 2019 May 14;21(1):61. doi: 10.1186/s13058-019-1141-0. Breast Cancer Res. 2019. PMID: 31088535 Free PMC article.
-
Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.Am J Surg Pathol. 2018 Mar;42(3):372-375. doi: 10.1097/PAS.0000000000000978. Am J Surg Pathol. 2018. PMID: 29112020 Free PMC article.
-
Does your gene need a background check? How genetic background impacts the analysis of mutations, genes, and evolution.Trends Genet. 2013 Jun;29(6):358-66. doi: 10.1016/j.tig.2013.01.009. Epub 2013 Feb 28. Trends Genet. 2013. PMID: 23453263 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
